Cargando…

Epigenetic control of CD1D expression as a mechanism of resistance to immune checkpoint therapy in poorly immunogenic melanomas

Immune Checkpoint Therapies (ICT) have revolutionized the treatment of metastatic melanoma. However, only a subset of patients reaches complete responses. Deficient β2-microglobulin (β2M) expression impacts antigen presentation to T cells, leading to ICT resistance. Here, we investigate alternative...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wang, Mona Meng, Koskela, Saara A., Mehmood, Arfa, Langguth, Miriam, Maranou, Eleftheria, Figueiredo, Carlos R.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2023
Materias:	Immunology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10106630/ https://www.ncbi.nlm.nih.gov/pubmed/37077920 http://dx.doi.org/10.3389/fimmu.2023.1152228

Ejemplares similares

Intratumoral CD73: An immune checkpoint shaping an inhibitory tumor microenvironment and implicating poor prognosis in Chinese melanoma cohorts
por: Gao, Zixu, et al.
Publicado: (2022)

TLR9 activation cooperates with T cell checkpoint blockade to regress poorly immunogenic melanoma
por: Reilley, Matthew J., et al.
Publicado: (2019)

CD83 expressed by macrophages is an important immune checkpoint molecule for the resolution of inflammation
por: Peckert-Maier, Katrin, et al.
Publicado: (2023)

Epigenetics Regulates Antitumor Immunity in Melanoma
por: Chen, Yuhan, et al.
Publicado: (2022)

Interleukin-33: Metabolic checkpoints, metabolic processes, and epigenetic regulation in immune cells
por: Lin, Jian, et al.
Publicado: (2022)

Poor CD4(+) T Cell Immunogenicity Limits Humoral Immunity to P. falciparum Transmission-Blocking Candidate Pfs25 in Humans
por: Zaric, Marija, et al.
Publicado: (2021)

Can Immunogenic Chemotherapies Relieve Cancer Cell Resistance to Immune Checkpoint Inhibitors?
por: Rivera Vargas, Thaiz, et al.
Publicado: (2019)

Dying to Be Noticed: Epigenetic Regulation of Immunogenic Cell Death for Cancer Immunotherapy
por: Cruickshank, Brianne, et al.
Publicado: (2018)

Pretreatment Innate Cell Populations and CD4 T Cells in Blood Are Associated With Response to Immune Checkpoint Blockade in Melanoma Patients
por: Pirozyan, Mehdi R., et al.
Publicado: (2020)

Landscape and Clinical Significance of Immune Checkpoint in Cutaneous Melanoma
por: Mao, Rui, et al.
Publicado: (2021)

Clonality of CD4(+) Blood T Cells Predicts Longer Survival With CTLA4 or PD-1 Checkpoint Inhibition in Advanced Melanoma
por: Arakawa, Akiko, et al.
Publicado: (2019)

Boiling histotripsy and in-situ CD40 stimulation improve the checkpoint blockade therapy of poorly immunogenic tumors
por: Singh, Mohit Pratap, et al.
Publicado: (2021)

Predicting HLA CD4 Immunogenicity in Human Populations
por: Dhanda, Sandeep Kumar, et al.
Publicado: (2018)

Role of Epigenetic Modifications in Inhibitory Immune Checkpoints in Cancer Development and Progression
por: Saleh, Reem, et al.
Publicado: (2020)

Low-dose immunogenic chemotherapeutics promotes immune checkpoint blockade in microsatellite stability colon cancer
por: Fang, Yuhang, et al.
Publicado: (2022)

The CD83 Molecule – An Important Immune Checkpoint
por: Grosche, Linda, et al.
Publicado: (2020)

Development and validation of immunogenic cell death-related signature for predicting the prognosis and immune landscape of uveal melanoma
por: Hu, Yuanyuan, et al.
Publicado: (2022)

From antimicrobial to anticancer: the pioneering works of Prof. Luiz Rodolpho Travassos on bioactive peptides
por: Koskela, Saara A., et al.
Publicado: (2023)

Whole Genome Expression Microarray Analysis of Highly Versus Poorly Tumorigenic Murine Melanoma Cell Lines Provides Insights into Factors That Regulate Tumor Growth, Metastasis, and Immunogenicity
por: Hargadon, Kristian Michael
Publicado: (2015)

Chromomycin A(5) induces bona fide immunogenic cell death in melanoma
por: Florêncio, Katharine Gurgel Dias, et al.
Publicado: (2022)

Genomic landscape of the immunogenicity regulation in skin melanomas with diverse tumor mutation burden
por: Georgoulias, George, et al.
Publicado: (2022)

Epigenetic modification-related mechanisms of hepatocellular carcinoma resistance to immune checkpoint inhibition
por: Tao, Shengwei, et al.
Publicado: (2023)

9-Gene Signature Correlated With CD8(+) T Cell Infiltration Activated by IFN-γ: A Biomarker of Immune Checkpoint Therapy Response in Melanoma
por: Yan, Kexin, et al.
Publicado: (2021)

B Cells in Patients With Melanoma: Implications for Treatment With Checkpoint Inhibitor Antibodies
por: Willsmore, Zena N., et al.
Publicado: (2021)

Sex Disparities of Genomic Determinants in Response to Immune Checkpoint Inhibitors in Melanoma
por: Shi, Fuyan, et al.
Publicado: (2021)

The immune checkpoint VISTA is associated with prognosis in patients with malignant uveal melanoma
por: Issam Salah, Nour el Imane, et al.
Publicado: (2023)

Immune Checkpoint Function of CD85j in CD8 T Cell Differentiation and Aging
por: Gustafson, Claire E., et al.
Publicado: (2017)

Novel Molecular Determinants of Response or Resistance to Immune Checkpoint Inhibitor Therapies in Melanoma
por: Zhang, Wenjing, et al.
Publicado: (2022)

Editorial: Improvement of melanoma immune checkpoint blockade therapy with potential combinatorial regiments
por: Wang, Xueyan, et al.
Publicado: (2022)

Safety and immunogenicity of a potential checkpoint blockade vaccine for canine melanoma
por: Kurupati, Raj K., et al.
Publicado: (2018)

Immunogenicity of Potential CD4(+) and CD8(+) T Cell Epitopes Derived From the Proteome of Leishmania braziliensis
por: e Silva, Rafael de Freitas, et al.
Publicado: (2020)

Distinct Age-Related Epigenetic Signatures in CD4 and CD8 T Cells
por: Hu, Bin, et al.
Publicado: (2020)

Comprehensive characterisation of immunogenic cell death in melanoma revealing the association with prognosis and tumor immune microenvironment
por: Ren, Jie, et al.
Publicado: (2022)

Digital expression profile of immune checkpoint genes in medulloblastomas identifies CD24 and CD276 as putative immunotherapy targets
por: Marques, Rui Ferreira, et al.
Publicado: (2023)

Differential Expression of Immune Checkpoint Modulators on In Vitro Primed CD4(+) and CD8(+) T Cells
por: Sabins, Nina C., et al.
Publicado: (2016)

Immune desert in MMR-deficient tumors predicts poor responsiveness of immune checkpoint inhibition
por: Zheng, Guoxing, et al.
Publicado: (2023)

The Role of m6A Epigenetic Modification in the Treatment of Colorectal Cancer Immune Checkpoint Inhibitors
por: Tong, Huan, et al.
Publicado: (2022)

Surveillance of SARS-CoV-2 immunogenicity: loss of immunodominant HLA-A*02-restricted epitopes that activate CD8(+) T cells
por: Lopes-Ribeiro, Ágata, et al.
Publicado: (2023)

Immune Checkpoint-Mediated Interactions Between Cancer and Immune Cells in Prostate Adenocarcinoma and Melanoma
por: Elia, Angela Rita, et al.
Publicado: (2018)

Combining Immune Checkpoint Inhibitors: Established and Emerging Targets and Strategies to Improve Outcomes in Melanoma
por: Khair, Duaa O., et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_nr5qvusp7986b5p0dal3io7b8j